Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance



    MARKHAM, ON, Sept. 16 /CNW/ - Cytochroma today announced that it has
appointed Steven I. Engel, M.S., Pharm.D., as Vice President, Regulatory
Affairs and Quality Assurance. Dr. Engel brings to Cytochroma over 20 years of
experience in regulatory affairs and quality assurance, and will be
responsible for directing all of Cytochroma's regulatory activities, as well
as ensuring that the Company has appropriate quality systems in place. He will
be based in Cytochroma's Illinois office.
    "Cytochroma's activities in the areas of clinical and regulatory affairs
are increasing significantly as we advance three lead product candidates
through clinical development," stated Charles W. Bishop, Ph.D., Cytochroma's
President and CEO. "For this reason, we have named Dr. Joel Melnick as Vice
President, Clinical Research and Development and assigned his former
responsibilities in the areas of regulatory affairs and quality assurance to
Dr. Steve Engel. Steve has a proven track record of successful new drug
registrations and post-marketing support, and we are pleased to have an
individual of this caliber helping us secure global regulatory approvals for
our products."
    Prior to joining Cytochroma, Dr. Engel was Vice President of Regulatory
Affairs and Clinical Quality Compliance at Par Pharmaceutical, Inc. where he
was responsible for the regulatory strategies of both branded and generic
pharmaceutical programs. Prior to joining Par Pharmaceutical, Dr. Engel held
regulatory positions at AlgoRx Pharmaceuticals, Vertex Pharmaceuticals, Baxter
Healthcare, Abbott Laboratories, Otsuka America Pharmaceuticals, G.D. Searle,
and American Cyanamid. He earned his Doctor of Pharmacy degree from the
University of Florida, his Master of Science in Pharmacology from the
University of North Carolina at Chapel Hill, and his Bachelor's degrees in
Pharmacy and Biology from Drake University.
    "Cytochroma's portfolio of therapies for chronic kidney disease has
tremendous potential," stated Dr. Engel. "I look forward to working with such
a skilled team to create a leading specialty pharmaceutical company."
    Cytochroma has a diverse portfolio of vitamin D-based therapeutics
designed to treat disorders related to abnormal or insufficient vitamin D
metabolism in chronic kidney disease (CKD) patients. These new products will
address target markets that are expected to grow significantly, reaching more
than $1.4 billion annually by 2013 in the U.S. alone. Cytochroma has three
product candidates in development for CKD patients: CTA018 and CTAP201 are
being developed for the treatment of secondary hyperparathyroidism (SHPT),
while CTAP101 is being developed for the treatment of vitamin D insufficiency.

    About Cytochroma

    Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and prevent
the clinical consequences of vitamin D insufficiency and SHPT associated with
CKD. The Company's vitamin D-based therapeutics are designed to safely and
effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma
is developing novel therapies to treat hyperphosphatemia in these same
patients.
    For more information, please visit www.cytochroma.com.





For further information:

For further information: Eric J. Messner, Vice President, Commercial
Operations, Tel: (847) 236-7707 ext. 238 (Bannockburn, IL), Tel: (905)
479-5306 ext. 338 (Markham, ON), eric.messner@cytochroma.com; Media Inquiries:
Robert Stanislaro (FD), Tel: (212) 850-5657, robert.stanislaro@fd.com

Organization Profile

Cytochroma

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890